Cargando…
Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by recurrent epistaxis, mucocutaneous telangiectasia, and arteriovenous malformations. The efficacy of traditional treatments for HHT is very limited. The aim of this study was to investigate the t...
Autores principales: | Peng, Hong-Ling, Yi, Yi-Fang, Zhou, Shun-Ke, Xie, Si-Si, Zhang, Guang-Sen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795244/ https://www.ncbi.nlm.nih.gov/pubmed/26608985 http://dx.doi.org/10.4103/0366-6999.169068 |
Ejemplares similares
-
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019) -
A Case Report of a Patient with Hereditary Hemorrhagic Telangiectasia Treated Successively with Thalidomide and Bevacizumab
por: Amanzada, Ahmad, et al.
Publicado: (2010) -
Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia
por: Colombo, G., et al.
Publicado: (2016) -
Hereditary Hemorrhagic Telangiectasia
por: Kamath, Nagesh, et al.
Publicado: (2015) -
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
por: Baysal, Mehmet, et al.
Publicado: (2019)